Episode summary
Episode 380: Joey Mason of Claret Capital on Venture Capital, Venture Debt and Europe's Need for ...
The Fiftyfaces Podcast
· · 38 min · Guests: Joey Mason
Summary
Joey Mason argues that Europe’s venture culture is too cautious with capital and too willing to let time slip by. He says the result is delayed decisions, underfunded companies, and slower progress, while the U.S. tends to value speed and accept faster failure when a business is not working. For him, venture capital is "the least inefficient way" to allocate capital, but only if it is run with urgency.
He explains Claret Capital’s role as a venture debt provider to late-stage biotech and specialty pharma companies, typically lending up to €50 million to firms in phase three, phase three-ready, or already commercial. He says the firm is looking for strong safety and efficacy signals, with the market having already de-risked the opportunity to a meaningful extent before Claret steps in.
Mason also argues that AI will touch every part of drug development, from discovery through clinical trials, but says the field is still early because biology remains too complex to model fully. On governance, he says boards should be disciplined, role-clear, and focused on management execution, because in venture, people and timing matter as much as finance.
Key takeaways
- Joey Mason says Europe should spend more and stop treating capital efficiency as a substitute for speed.
- He says Claret Capital lends up to €50 million to late-stage biotech and specialty pharma companies, mainly alongside equity investors.
- Mason says phase three biotech risk is materially lower than earlier stages, with roughly 50% to 60% probability of success by that point.
- He argues AI can accelerate drug development across discovery and trials, but proprietary data and execution will separate winners.
- Mason says good boards are disciplined and binary: once confidence in a CEO is lost, the relationship changes fundamentally.
Notable quotes
“I think in Europe we need to be far more open to the idea that you have to spend more and perhaps lose more but you will gain more in a weird way”
“Venture capital is bit like democracy. It's the least inefficient way we have of allocating capital”
“Clarit is a venture debt fund. We lend to companies that are in the biotech world. They're late stage clinical”
“By the time we're involved, companies will have brought the drugs through phase two”
“I think in Europe we need to be far more open to the idea that you have to spend more and perhaps lose more but you will gain more in a weird way”
How the episode opens
We have a tendency in Europe to be far more cautious with how much money we allocate and companies trying to survive on very limited capital and all it does is delay things. Decisions get put off. Important activities don't take place because people are saving money and I just think it's the wrong approach.
I think in Europe we need to be far more open to the idea that you have to spend more and perhaps lose more but you will gain more in a weird way. Venture capital is bit like democracy. It's the least inefficient way we have of allocating capital.
How do you make it as efficient as possible? And really I think time is the enemy. We need to understand that.
I'm Ethan Devid and welcome to the 50 Faces podcast. A podcast committed to revealing the richness and diversity of the world of investment by focusing on its people and their stories. This podcast is kindly supported by Bailey Gford and UCM Groner.
In a world that moves at an unrelenting pace, where the horizons of innovation stretch beyond what the eye can see, Bailey Gford is driven by curiosity. As long-term growth investors, they are searching for hidden gems, the future winners yet to be realized, the winners in their fields, those companies with foundations built to last. Only the patient can see past the temporary and distracting.
As an aligned partnership that resists the seduction of short-term gains, Bailey Gford seeks out companies that will not only succeed, but do so by addressing the needs of society and driving change toward the next horizon. As active investors, Bailey Gford are not just spectators. They are partners in the narrative of progress.
GCM Groner is a global alternative asset management solutions provider with more than $90 billion in assets under management across private equity, infrastructure, real estate, credit, and absolute return strategies.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- venture capital
- venture debt
- biotech investing
- europe vs us venture ecosystems
- speed and execution in europe
Companies and tickers mentioned
- Claret Capital Partners
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from The Fiftyfaces Podcast
-
Episode 385: Roy Kuo of Galilei Family Office: Thinking like an Owner in the Family Office Arena -
Episode 384: Nadine Buckland of Zenzic Capital - Unlocking the potential of real estate debt -
Episode 383: BONUS EPISODE: Art as a Strategic Imperative - Vadim Grigoryan of Art Thinking -
Episode 382: Christian Abuide - The Future of WealthTech -
Episode 377: Keith Williams of Crestline Investors: Striking a Balance in Private Credit and in Life -
Episode 378: Anwiti Bahuguna of Northern Trust: The Golden Era of Customisation
The Fiftyfaces Podcast, this episode and its artwork belong to Aoifinn Devitt. Octagon is not affiliated with the show; this page is an independent summary.
